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Statement of translational relevance  
Antibodies against PD-1 have revolutionized cancer immunotherapy. This article describes relevant 
skin toxicities emerging upon treatment with antibodies against PD-1 such as nivolumab and 
pembrolizumab. Skin toxicities were classified using histology and gene expression profiling in 
comparison to mild maculopapular drug rashes and severe drug eruptions such as toxic epidermal 
necrolysis. Although the clinical picture was variable ranging from mild to severe gene expression 
profiling resembled in all cases to severe cytotoxic SJS/TEN-like patterns. This suggests that the PD-
1/PD-L1 interaction is involved in the preservation of epidermal integrity during inflammatory skin 
reactions. We advocate a careful examination of the skin of patients treated with immunotherapy in the 
near future as these adverse cutaneous reactions can imply a loss of epidermal integrity.  
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Abstract 
Purpose:  
Immunotherapy experienced impressive progresses in cancer treatment. Antibodies against PD-1 
improved survival in different types of cancer including melanoma. They are generally well tolerated. 
However, skin toxicities including pruritus, rashes and vitiligo are reported. Although frequent, they are 
have not been further characterized yet. In this analysis we aimed to systematically assess and 
characterize the adverse cutaneous reactions observed in melanoma patients treated with anti-PD-1 
antibodies. 
Experimental Design: 
Melanoma patients were treated with anti-PD-1 antibodies within clinical trials and early access 
program. Adverse cutaneous eruptions emerged in our melanoma patient cohort were systematically 
investigated and classified using histology and gene expression profiling in comparison to 
maculopapular drug rash, cutaneous graft versus host disease and the severe drug eruption toxic 
epidermal necrolysis. 
Results: 
Between Feb 2013 and Sept 2015, 68 stage IV melanoma patients were treated at the University 
Hospital Zurich; 15 patients (22%) developed cutaneous reactions and 10 (15%) vitiligo. The 
cutaneous reactions ranged from small erythematous papules with mild pruritus to disseminated 
erythematous maculopapular rashes without signs of epidermal involvement to severe maculopapular 
rashes including epidermal detachment and mucosal involvement. Although skin involvement varied 
from mild rash to bullous drug eruptions, gene expression profiling pathogenically classified all 
investigated cases as toxic epidermal necrolysis-like reactions. 
Conclusions: 
As predicted by the PD-1 knock out mouse, anti-PD-1 antibodies frequently cause adverse cutaneous 
reactions. Gene expression profiling reminds in all cases to a toxic epidermal necrolysis-like pattern 
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suggesting that PD-1/PD-L1 interaction is required to preserve epidermal integrity during inflammatory 
skin reactions. 
Funding: University of Zurich
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Introduction 
Antibodies against PD-1, a checkpoint in the effector phase of cytotoxic T cells, have been 
successfully used in cancer immunotherapy(1-3). Through the binding to PD-1, its ligands, namely PD-
L1 and PD-L2, inhibit T cell-mediated immune responses. By preventing the binding of PD-L to PD-1, 
the FDA-approved antibodies pembrolizumab and nivolumab promote T cell-mediated cytotoxic 
responses which result in tumor regression in a variety of cancers(2). In several randomized pivotal 
studies pembrolizumab and nivolumab demonstrated improved overall response rates and 
progression-free survival compared to chemotherapy or the anti-CTLA-4 antibody ipilimumab(4-7). 
Besides efficacy, the introduction of anti-PD-1 antibodies led to a new benchmark for treatment 
tolerability in cancer being a treatment with very few adverse events. Adverse cutaneous reactions 
have however been reported. These include skin exanthemas with a frequency of 10-25% and vitiligo 
in 9-11% of the treated patients(2, 4, 5). Robert et al. hypothesize that vitiligo is associated with a 
favorable outcome of anti-PD-1 therapy(8). Moreover, one case of bullous pemphigoid in association 
with pembrolizumab(9) and one case of psoriasiform exanthema under nivolumab(10) have been 
published. The adverse cutaneous reactions observed under the treatment with anti-PD-1 antibodies 
have not been characterized in detail so far.  
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous drug 
eruptions characterized by widespread macules, papules and/or targetoid lesions with varying degrees 
of epidermal necrolysis clinically presenting as skin detachment and/or bullous skin lesions with 
mucosal erosions(11). Common drugs inducing SJS/TEN include allopurinol, trimethoprim-
sulfamethoxazole, carbamazepin, lamotrigine, nevirapin, NSAIDS, phenobarbital and phenytoin(12). 
The molecular events that cause potentially fatal SJS and TEN are only partially understood, although 
"drug"-specific adaptive immune responses in the effector phase of TEN are well documented(13). In 
the skin, T cell-mediated immune responses occurring during SJS/TEN result in a massive 
keratinocyte apoptosis mediated by cytolytic molecules including FasL(14), perforin/granzyme B(15), 
annexin A1(16) and granulysin(17). Histologically SJS and TEN are characterized by full-thickness 
epidermal necrolysis due to extensive keratinocyte apoptosis associated with varying degrees of 
inflammation and epidermal infiltration by CD8+ lymphocytes.  
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In this study we aimed to systematically assess and characterize the adverse cutaneous reactions 
observed in advanced melanoma patients treated with anti-PD-1 antibodies using gene expression 
profiling and compared the data to other clinical types of drug eruptions.  
 
Patients and Methods 
Advanced melanoma patients were treated with either the anti-PD-1 antibody pembrolizumab (2mg/kg 
or 10mg/kg) or with nivolumab (3mg/kg) within clinical trials (clinicaltrials.gov NCT01704287, 
NCT01721746 and NCT02156804)(4, 7) and early access program. The first 68 melanoma patients 
treated with pembrolizumab or nivolumab at the University of Zurich were systematically investigated 
for adverse skin reactions by board certified dermatologists experienced in immunotherapy and 
familiar with associated adverse events (SMG and/or RD). 
Complete and accurate skin examinations were performed before and during immunotherapy. 
Selected previously untreated skin eruptions of 8 patients emerging during therapy were biopsied and 
analyzed by histology. The decision to take a biopsy was based on whether the lesion was new (i.e. 
not apparent prior treatment start), on the severity (grade 2 or greater), on the localization and 
distribution (favoring multiple and disseminated lesions) and on the clinical characteristics (palpable or 
scaling presentation). In general, the most infiltrated lesion was chosen and biopsied provided 
patient’s consent and that the lesion was in a region of the body that allowed proper wound healing. 
Expression of PD-1 on skin infiltrating T-cells (eBioscience, San Diego, CA) and PD-L1 
(Immunobiology Yale, New Haven, CT) on keratinocytes at the foci of lymphocytic epidermal infiltration 
was assessed by immunohistochemistry. 
Gene expression analysis of 5 out of these 8 skin biopsies during anti-PD-1 therapy with 
pembrolizumab were in addition analyzed and compared to expression profiles of skin biopsies from 
patients with maculopapular rashes (MPR) (n=8), SJS/TEN (n=5), and cutaneous graft-versus-host 
disease (GVHD) (n=9). RNA was isolated from patients skin (n=5) and from healthy control skin (n=4) 
using a Qiagen RNeasy kit (Qiagen) following manufacturer's instructions, and total RNA was 
converted into cDNA by standard reverse transcription using a RevertAid RT Reverse Transcription Kit 
(Thermo Scientific). Quantitative PCR was performed using Power SYBR Green PCR Master Mix 
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(Applied Biosystems). Primer sequences were obtained from http://pga.mgh.harvard.edu/primerbank/. 
The real-time PCR included an initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C 
for 30 s, 56°C for 1 min, 72°C for 1 min, and one cycle of 95°C for 1 min, 56°C for 30 s, 95°C for 30 s. 
Moreover, we performed gene expression arrays (Affymetrix) on skin of MPR patients (n=8), SJS/TEN 
patients (n=5), GVHD patients (n=9) and healthy donors (n=8) as controls. Healthy skin was obtained 
from healthy individuals undergoing plastic surgery. All human skin biopsies were collected with 
informed written consent upon approval of local ethical committees and were conducted according to 
the Declaration of Helsinki Principles (KEK Nr. 647). Based on the results of the gene expression 
arrays, we selected a set of genes that could be used as specific signature for TEN as opposed to 
MPR and GVHD (Figure 2A). Using quantitative RT-PCR we determined the expression levels of the 
gene set specific for SJS/TEN in the skin of patients with an adverse cutaneous reaction occurring 
during anti-PD-1 therapy. 
 
Results 
Between Feb 2013 and Sept 2015, 68 patients were treated with either pembrolizumab 2mg/kg, 
10mg/kg (every three weeks), or nivolumab 3mg/kg (every two weeks) in different clinical trials 
(clinicaltrials.gov NCT01704287, NCT01721746 and NCT02156804)(4, 7) and early access program. 
Out of the first 68 stage IV melanoma patients treated with pembrolizumab (n=54) or nivolumab (n=14) 
at the University Hospital of Zurich 15 patients (22%) developed any cutaneous inflammatory reaction 
and 10 (15%) a vitiligo. Clinically, the adverse cutaneous reactions ranged from small erythematous 
papules with mild pruritus to disseminated erythematous maculopapular rashes without major clinical 
signs of epidermal involvement to severe maculopapular rashes including epidermal detachment and 
mucosal involvement (Table 1). Histology performed on selected lesional skin biopsies of 8 patients at 
onset of the adverse cutaneous reaction revealed different manifestation grades of apoptotic 
keratinocytes and even focal full thickness necrosis of the epidermis in two cases in the histology 
(Table 1). In particular, a 77 year-old patient presented with a generalized unspecific maculopapular 
rash predominantly affecting the trunk with focal areas of epidermal detachment a few days after the 
first pembrolizumab infusion (Figure 1A, <10% of the body surface area). Histology showed epidermal 
damage with apoptotic keratinocytes, subepidermal lymphocytic infiltrates and dermo-epidermal 
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cleavage (Figure 1B). One week later, mucosal involvement and genital ulcerations developed. Taken 
together these features led to a diagnosis of SJS, and pembrolizumab therapy was discontinued.  
Skin biopsies from six patients were also analyzed by immunohistochemistry and revealed in all cases 
an accumulation of CD8+ cells at the dermo-epidermal junction and some CD8+ exocytosis within the 
epidermis, as well as keratinocyte apoptosis suggestive of a cytotoxic etiology. Expression of PD-1 on 
skin infiltrating T-cells and keratinocytes at the foci of lymphocytic epidermal infiltration was also 
assessed by immunohistochemistry (Figure 1C/1D). Despite topical steroids, the lesions of this patient 
subsequently evolved into persistent polygonal flat erythematous papules, clinically suggestive of 
lichen planus (Figure 1E). Accumulation of cytotoxic CD8+ lymphocytes in the junction zone and in the 
epidermis causing apoptotic cell death of keratinocytes, classical for lichen planus, was confirmed by 
histology (Figure 1F). PD-L1 expression on keratinocytes was clearly detectable by 
immunohistochemistry in the proximity of T-cells (Figure 1G/1H).  
In all cases, none of the concomitant medications taken by patients had been recently started or were 
known to cause SJS/TEN (Table 1). Furthermore, lymphocyte transformation tests to the concomitant 
medication taken by the patient 1 did not provide evidence for a "drug"-specific immune response 
(data not shown) (Table 1).  
Treatment included systemic steroids (prednisone 1mg/kg, tapered for 4 weeks), systemic steroids 
(over a course of 4 weeks), disinfectant agents when necessary, and re-hydratation of the skin. 
Treatment with pembrolizumab could be continued in 4/6 cases and did not further affect the skin. 
Gene expression profiling of RNA extracted from lesional skin of validated cases of MPR (8 cases), 
SJS/TEN (5 cases) and cutaneous GVHD (9 cases) enabled us to identify a set of 18 genes for which 
the expression levels enable differentiation between the three diagnostic categories (Figure 2A). 
Analysis of the level of expression of these 18 genes was performed in the lesional skin biopsies of 5 
patients, and revealed a gene expression profile reminiscent of SJS/TEN (Fig 2B). Both SJS/TEN skin 
(n=5) and skin of 5 patients presenting an adverse cutaneous reaction upon anti-PD-1 therapy had 
significant upregulation of Elafin, SPRR2B, Granzyme B, CXCL9, CXCL10 and CXCL11 whereas 
expression of Desmocollin 3, Loricrin, Filaggrin and Keratin 1 were similar to those in healthy skin. 
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Differences were seen in the expression levels of CCL27, NURR1, GNLY, FasL and Perforin which 
were all upregulated in the skin of the 5 anti-PD-1 patients but not in SJS/TEN skin (Figure 2B).  
Taken together our clinical, histological, immunohistological and gene expression analyses provide 
evidence that the adverse cutaneous reactions observed in patients treated with anti-PD-1 antibodies 
is reminiscent of SJS/TEN, and points to a role for PD-1 in regulating cytotoxic T-cell responses in the 
skin.  
 
Discussion 
The crosstalk between cancer cells and immune cells of the tumor microenvironment is crucial for the 
outcome of anti-tumor immune responses and immunotherapy. In various cancers, these interactions 
often result in a local immunosuppression resulting in the escape of tumor cells from immune-
surveillance. The use of checkpoint inhibitors such as antibodies to PD-1 leads to significant clinical 
benefits by inducing advanced and metastatic tumor regression. Although anti-PD-1 antibody therapy 
is safe and well tolerated in melanoma patients(2, 18-20), adverse cutaneous reactions have been 
reported(2, 4, 9, 10, 21). Here, we report and describe adverse cutaneous reactions during anti-PD-1 
immunotherapy with pembrolizumab. In 22% of the patients, which is more than reported in clinical 
trials(4, 7, 21), we observed inflammatory skin lesions ranging from mild maculopapular rashes, 
typically associated with scaling and/or lichenoid lesions to very severe SJS-like skin lesions that did 
slowly improve and resulted in a chronic lichen planus.  
Clinical and histological features of the lesions striking resemble the findings reported in mice with a 
disrupted PD-1 gene(22). These mice develop a lupus-like inflammatory syndrome with proliferative 
glomerulonephritis, arthritis with sometimes granulomatous inflammation and skin lesions- reported as 
“dermatitis-like lesions, necrotic lesions and erythema”(22). The histologies of the skin of these mice 
present features compatible with lichen planus including acanthosis, hypergranulosis and apoptotic 
keratinocytes together with a lymphocytic infiltrate of the grenz zone of the basal membrane resulting 
in a vacuolization and sometimes split formation(22).  
The histological analysis of these human adverse cutaneous reaction cases demonstrated signs of a 
cytotoxic skin eruption characterized by an accumulation of CD8+ T-cells at the dermo-epidermal 
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junction and CD8+ T-cell exocytosis into the epidermis with apoptotic keratinocytes. These features 
can also be observed in severe immune-mediated skin diseases such as acute GVHD and SJS/TEN. 
Gene expression analysis of lesional skin from anti-PD-1-treated patients revealed a gene expression 
profile resembling SJS/TEN with an upregulation of major inflammatory chemokines such as CXCL9, 
CXCL10 and CXCL11, of cytotoxic mediators such as Perforin and Granzyme B and the pro-apoptotic 
molecule FasL, as well as an upregulation of PD-L1 which was confirmed by immunohistochemistry in 
3 cases. In contrast, the expression pattern of selected genes in the skin lesions of anti-PD-1-treated 
patients was different from that seen in acute GVHD and MPR. Therefore, clinical, histological, 
immunohistological, and gene expression analyses strongly suggest that, at least in some patients, 
anti-PD-1 antibody can induce SJS/TEN-like adverse cutaneous reactions.  
The intensity of the immune mediated tissue damage varies and is interindividual - a possible 
explanation could be the genetic predisposition and variation based on single nucleotide 
polymorphisms in genes related to immune functions. These genetic background alterations can 
cause differences in the susceptibility to develop cutaneous drug reactions. 
The exact pathomechanism of the adverse cutaneous reactions occurring upon pembrolizumab and 
nivolumab therapy remains to be elucidated. While vitiligo can be considered as a successful (re)-
activation of T cells with a repertoire specific to melanocyte antigens, the induction of a cytotoxic 
response to keratinocytes was not expected, and is indicative of the activation of T cells with non-
melanoma-derived self-antigen specificity(ies). Interestingly, both vitiligo and/or cutaneous reactions 
emerging during nivolumab treatment in melanoma patients have recently been reported to be 
associated with overall survival(23). As a consequence, cutaneous reactions during anti-PD-1 
treatment could potentially be used as biomarkers in the therapy. Although larger prospective analyses 
are still needed to validate this association, detection and diagnosis of cutaneous reactions during 
anti-PD-1 therapy gain further importance in this context. By inhibiting T cell activation and sustaining 
Tregs(24), the PD-1/PD-L pathway plays a major role in peripheral tolerance including transplant(25) 
and feto-maternal tolerance(26). The concept of a tolerogenic role for PD-1/PD-1L has emerged from 
observations that PD-1-deficient mice develop autoimmune pathologies(27) including lichenoid 
reactions(22). One could hypothesize that, at the steady state, PD-1/PD-L interactions are crucial for 
the homeostasis of T cells in the skin and for preventing severe skin-directed inflammatory reactions 
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from occurring. In line with this, it has been recently reported that, in a mouse model that PD-L1 
expressed on keratinocytes presenting self-antigens, regulates autoreactive CD8+ T cell activity, and 
prevents the development of cutaneous autoimmune disease(28). The reason for which cutaneous 
adverse events in anti-PD-1-treated patients can vary from vitiligo to SJS-like reactions remains 
unknown and larger series of subjects would be required to assess this. A detailed characterization of 
the T cells causing damage to healthy tissues in patients treated with anti-PD-1 antibodies as well as 
complementary skin investigations in patients without adverse skin reactions would be of interest for a 
better understanding and, ultimately, the prevention of such severe forms of adverse cutaneous 
reactions.  
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Figure and Table legends:  
 
Table 1. Patients’ characteristics including clinical and histological presentation. 
 
Figure 1. Clinical and histological presentation of a metastatic melanoma patient developing a 
severe adverse cutaneous reaction (ACR) upon treatment with pembrolizumab. a-d. Stevens-
Johnson Syndrome (SJS), e-h. Lichen planus.  
a. Clinical features of SJS; b. Histology of SJS (hematoxylin-eosin stain); c. PD-1 stain of SJS; d. PD-
L1 stain of SJS. e. Clinical features of lichen planus; f. Histology of lichen planus; g. PD-1 stain of 
lichen planus; h. PD-L1 stain of lichen planus. 
 
Figure 2. Gene expression profiling. a  The mRNA expression levels of 6564 different genes were 
measured in lesional skin of MPR (n=8), Lyell (n=5) and GVHD (n=9) patients and skin of healthy 
donors (n=8) using the Affymetrix Human Transcriptome Array 2.0. The relative expression levels 
were normalized to healthy skin and indicated as fold change (2-ΔΔCt ). b. The mRNA expression levels 
of selected genes were measured in lesional skin of patients developing a skin drug eruption under 
anti-PD-1 therapy (n=5). The relative expression levels were normalized to healthy skin (n=4) and 
indicated as fold change (2-ΔΔCt ). Statistical analyses were performed using the student’s t-test.          * 
indicates a p-value ≤ 0.05, ** indicates a p-value ≤ 0.01, *** indicates a p-value ≤ 0.001, **** indicates 
a p-value ≤ 0.0001. 
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Table 1. Patients' characteristics, Clinical Presentation and Histology of the adverse cutaneous reactions
Characteristics 
(m/f; age (y))
Onset 
(weeks after starting 
anti-PD-1 abs)
Clinical Presentation Histology Concomittant medication Other possibly treatment related adverse reactions
Discontinuation of 
pembrolizumab
(yes/no)
Treatment of the adverse 
cutaneous drug reaction
Patient 1 m; 76 1 (after 1 infusion)
Maculopapular rash evolving 
into subepidermal blister 
formation including mucosal 
involvement with pain and 
pruritus, evolving into lichen 
planus
4 biopsies over time:
1.Lichenoid dermatitis with accumulation of 
CD8+ cells at the dermo-epidermal junction and  
CD8+ exocytosis and focal keratinocytic 
apoptosis
2. Lichenoid inflammation with vacuolization of 
junction zone and keratinocytic apoptosis
3. Lichenoid accumulation of cytotoxic CD8+ 
lymphocytes in the junction zone and in the 
epidermis with apoptotic keratinocytes
4. Lichenoid inflammation with hyperkeratosis 
resembling lichen verrucosus
Phenprocoumon; Spironolactone; 
Acetylsalicylic acid; Bisoprolol; 
Metamizole*; Rabeprazole; Mitrazapine; 
Lorazepam; Torasemide, Ramipril; 
Oxycodone*; Dalteparin**
none yes
Systemic Prednisone 1mg/kg 
(tapering for 4 weeks);
Topical Steroids, including oral 
application for 4 weeks; 
Topical disinfectants 
(Panthenol, 
    Hyaluronate Sodium with 
Silver Sulfadiazine; 
Chlorhexidine)
Skin hydratation
Patient 2 m; 66 6 (after 3 infusions) Disseminated maculopapular rash with moderate pruritus
Lichenoid drug reaction with follicular 
accentuation
focal spongiosis and CD8+ exocytosis 
Fluticasone/Salmeterol; Salbutamol Vitiligo no Topical steroids for 4 weeks; Skin hydratation
Patient 3 m; 50 5 (after 3 infusions)
Disseminated maculopapular 
rash with main focus on the 
trunc and neck. No pruritus.  
Lichenoid dermatitis with vacuolization of junction 
zone and focal keratinocyte apoptosis Pantoprazole***; Bisoprolol*** Anaemia (haemolysis) yes (due to anaemia) Topical steroids for 4 weeks; Skin hydratation
Patient 4 m; 82 1 (after 1 infusion)
Small erythematous papules 
with moderate pruritus
Lichenoid  dermatitis with CD8+ cells in the 
dermo-epidermal junction and focal full thickness 
necrosis
Phenprocoumon none no Skin hydratation
Patient 5 m; 72 51 (after 17 infusions)
Psoriasiform disseminated skin 
lesions predominantly on the 
lower extremities both sides. 
Mild pruritus
2 biopsies over time:
1. Focal acanthosis and spongiosis and some 
apoptotic keratinoytes with lichenoid aspect
2. Lymphocytic infiltration of the adnexa
Simvastatin; Losartan; Chondroitin sulfate Vitiligo no Topical steroids for 4 weeks; Skin hydratation
Patient 6 m; 78 21 (after 7 infusions)
Focal erythematous plaques on 
the trunk and on the neck with 
mild pruritus
Lichenoid drug reaction with lymphocytic infiltrate 
and few eosinophils
Candesartan; Acetylsalicylic acid; 
Atorvastatin Vitiligo no
Systemic Prednisone 1mg/kg 
(tapering over 2 weeks); 
Topical steroids for 4 weeks; 
Skin hydratation
Patient 7 m; 58 9 (after 3 infusions)
Focal erythematous plaques on 
the lower leg with mild pruritus Lymphocytic perivascular sleeve-like inilftrates and lichenoid inflammation with spongiosis Lisinopril; Ibuprofen; Xylometazoline Vitiligo no
Topical steroids for 2 weeks; 
Skin hydratation
Patient 8 f; 66 60 (after 21 infusions)
Focal erythematous papule 
with moderate pruritus on the 
back
Acanthosis, papillomatosis and lichenoid 
inflammation Losartan none no Skin hydratation
* Start 8 weeks before onset 
** Start 1 week before onset 
*** Start 4 weeks before onset 
o
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